J&J Medical Connect
DARZALEX FASPRO®

(daratumumab and hyaluronidase-fihj)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)
Medical Information

DARZALEX FASPRO - Progression-Free Survival (PFS) Projections from the PERSEUS and CEPHEUS Studies

Last Updated: 11/18/2026

Summary

  • Johnson & Johnson does not recommend the use of DARZALEX FASPRO in a manner that is inconsistent with the approved labeling.
  • PERSEUS is a phase 3 study evaluating the efficacy and safety of DARZALEX FASPRO in combination with bortezomib, lenalidomide, and dexamethasone (D-VRd) vs bortezomib, lenalidomide, and dexamethasone alone (VRd) induction and consolidation followed by maintenance with DARZALEX FASPRO and lenalidomide (D-R) in the D-VRd group or lenalidomide alone (R) in the VRd group in patients with newly diagnosed multiple myeloma (NDMM) eligible for autologous stem cell transplant (ASCT). At a median follow-up of 47.5 months, 14.1% of patients in the D-VRd arm vs 29.1% of patients in the VRd arm experienced disease progression or death (hazard ratio [HR], 0.42; 95% confidence interval [CI], 0.30-0.59; P<0.0001). At a median follow-up of 81.3 months, the median PFS was not reached (NR) in the D-VRd arm vs 81.45 months in the VRd arm (HR, 0.35; 95% CI, 0.26-0.46; P<0.0001).1,2
  • CEPHEUS was a phase 3 study evaluating the efficacy and safety of D-VRd vs VRd alone in patients with NDMM who were transplant ineligible (TIE) or for whom transplant was not planned as initial therapy (transplant deferred). At a median follow-up of 58.7 months, D-VRd improved PFS vs VRd, with a 43% reduction in the risk of progression or death (HR, 0.57; 95% CI, 0.41-0.79; P=0.0005). The median PFS for the D-VRd arm was NR vs 52.6 months for the VRd arm.3
  • Sonneveld et al (2026)4 published the results of an analysis designed to model the median PFS projections based on the PERSEUS intention-to-treat (ITT) and CEPHEUS TIE populations. The best-fit exponential distribution modeled a longer projected median PFS for D-VRd vs VRd for both the PERSEUS (17.1 years vs 7.3 years) and CEPHEUS (8.3 years vs 4.4 years) populations.

CLINICAL STUDIES

PFS Projection Models of the PERSEUS and CEPHEUS Studies

Sonneveld et al (2026)4 published the results of an analysis designed to model the long-term median PFS projections based on the PERSEUS ITT and CEPHEUS TIE populations.

Methods

  • Data from the PERSEUS ITT population (N=709; D-VRd [n=355]; VRd [n=354]) and the CEPHEUS TIE subgroup (N=289; D-VRd [n=144]; VRd [n=145]) were used.4
  • PFS modeling was conducted according to the United Kingdom (UK) National Institute for Health and Care Excellence (NICE) guidance on survival data extrapolation.4
  • Seven standard parametric models (exponential, Weibull, gamma, Gompertz, log-logistic, log-normal, generalized gamma) were fitted to extrapolate PFS data, and a best-fit model projection was determined.4
  • UK general mortality data were considered and PFS projections were truncated based on estimated life expectancy.4
  • The exponential model, which was chosen as best-fit for both study populations, assumes a constant hazard which is not reflective of the relapsing nature of multiple myeloma.4

Results

PERSEUS
  • Across the 7 models, median PFS projections were longer with D-VRd vs VRd, ranging from 13.2-21.2 years for D-VRd and 6.3-9.9 years for VRd.4
  • The best-fit distribution was the exponential model, projecting a median PFS of 17.1 years vs 7.3 years for D-VRd vs VRd, respectively, in transplant-eligible NDMM.4
CEPHEUS
  • Across the 7 models, PFS projections were longer with D-VRd vs VRd, ranging from 8.0-9.8 years for D-VRd and 4.3-4.5 years for VRd.4
  • The best-fit distribution was the exponential model, projecting a median PFS of 8.3 years vs 4.4 years for D-VRd vs VRd, respectively, in TIE NDMM.4

LITERATURE SEARCH

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File databases (and/or other resources, including internal/external databases) was conducted on 10 November 2026.

 

References

1 Sonneveld P, Dimopoulos MA, Boccadoro M, et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;390(4):301-313.  
2 Sonneveld P, Dimopoulos M, Boccadoro M, et al. Long-term outcomes with daratumumab, bortezomib, lenalidomide, and dexamethasone  (DVRd) versus VRd in transplant-eligible newly diagnosed multiple myeloma (TE-NDMM) in the phase 3 PERSEUS study. Oral Presentation presented at: the 23rd International Myeloma Society (IMS) Annual Meeting; September 23-26, 2026; Glasgow, Scotland.  
3 Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat Med. 2025;31(4):1195-1202.  
4 Sonneveld P, Zweegman S, Facon T, et al. Modeling long-term progression-free survival in newly diagnosed multiple myeloma treated with daratumumab, bortezomib, lenalidomide, and dexamethasone. J Clin Oncol. 2026. doi:10.1200/jco-26-00384.  

Would you like to clear and leave your conversation? Message history will be lost.